Bristol Myers Squibb (NYSE: BMY) reported Phase 3 trial results showing its drug Zenbexus (iberdomide) combined with daratumumab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE